Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy of a Combination of Telmisartan/S-Amlodipine Compared With Telmisartan Monotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. More than 19 years in hypertension patient~2. Hypertension is satisfied with the Clinic blood pressure that was measured at the time of randomization~   * Clinic MSSBP ≥ 140mmHg~  * Clinic MSSBP ≥ 130mmHg in diabetes mellitus or chronic kidney disease~     * Diabetes mellitus~       * Before screening, diagnosed with diabetes mellitus being treated with oral hypoglycemic agents at least 30 days OR~      * Patients who meet the following results of laboratory tests at the time of randomization. : Fasting plasma glucose ≥ 126mg/dL~    * Chronic kidney disease~       * Patients who meet the following results of laboratory tests at the time of randomization.: 15mL/min/1.73m2 ≤ estimated glomerular filtration rate ≤ 60mL/min/1.73m2~3. Patient who decided to participate and signed on an informed consent form willingly~Exclusion Criteria:~1. Clinic MSSBP ≥ 200mmHg or Clinic MSDBP ≥ 120mmHg at the time of Screening and Randomization~2. As night workers who sleep during the day and whose working hours including 00:00 to 04:00~3. Abnormal laboratory test results~   * Aspartate aminotransferase/Alanine aminotransferase \> Upper normal limit X 3~  * Serum creatinine \> Upper normal limit X 4~4. Secondary hypertension patient without diabetes mellitus, chronic kidney disease: coarctation of aorta, cushing's syndrome, pheochromocytoma, primary aldosteronism etc.~5. Severe heart disease(Heart failure; New York Heart Association(NYHA) class 3, 4) and recent unstable angina or myocardial infarction or valvular heart disease or arrhythmia requiring treatment within the past 3 months~6. Severe cerebrovascular disorders such as cerebral infarction, cerebral hemorrhage within 6 months~7. Patient who is planning for a renal transplantation during the trial~8. Severe or malignant retinopathy~9. Acute of chronic inflammatory status requiring treatment~10. A history of cancer within five years~11. A history of angioedema with ACE inhibitors or angiotensin-Ⅱ receptor blockers~12. Severe hypersensitivity to amlodipine or telmisartan~13. Surgical or medical conditions~    * History of major gastrointestinal surgery~   * History of active inflammatory bowel syndrome within 12 months~   * Abnormal pancreatic functions~   * Gastrointestinal/rectal bleeding~   * Urinary tract obstruction~14. Need for other antihypertensive drugs during the trial~15. Need for prohibited medication specified in the protocol~16. Administration of other Investigational Product within 30 days~17. History of drug or alcohol abuse within 6 months~18. Pregnant, breast-feeding and childbearing age who don't use adequate contraception~19. Another clinical condition in investigator's judgement

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Telminuvo®Tab. 40/2.5mg (Type: EXPERIMENTAL): Telminuvo®Tab.(Telmisartan/S-Amlodipine) 40/2.5mg
- Telmitrend®Tab. 80mg (Type: ACTIVE_COMPARATOR): Telmitrend®Tab.(Telmisartan) 80mg

Based on this trial design, predict the completion outcome and termination type (if applicable).